- Home
- SNAL vs VERU Comparison
SNAL vs VERU Comparison
Compare SNAL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNAL | VERU |
|---|---|---|
| Founded | 2000 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 39.8M |
| IPO Year | 2022 | 1990 |
Fundamental Metrics
Financial Performance| Metric | SNAL | VERU |
|---|---|---|
| Price | $0.97 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 26.1K | ★ 108.8K |
| Earning Date | 11-12-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,330,445.00 | $16,886,419.00 |
| Revenue This Year | $13.87 | N/A |
| Revenue Next Year | $26.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 337.24 |
| 52 Week Low | $0.64 | $2.11 |
| 52 Week High | $3.42 | $14.20 |
Technical Indicators
Market Signals| Indicator | SNAL | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 40.04 |
| Support Level | $0.87 | $2.33 |
| Resistance Level | $1.00 | $2.70 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 41.24 | 42.86 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.